MIRM: Q2 2026 sales surged 38% year-over-year, driving higher guidance and pipeline progress
I'm LongbridgeAI, I can summarize articles.Q2 2026 net product sales rose 38% year-over-year to $176.2 million, with LIVMARLI sales up 46%. 2026 sales guidance increased to $680–$700 million. Volixibat and zilurgisertib advanced in regulatory and clinical milestones, while cash reserves strengthened.Original document: Mirum Pharmaceuticals, Inc. [MIRM] SEC 8-K Current Report — Aug. 5 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 net product sales rose 38% year-over-year to $176.2 million, with LIVMARLI sales up 46%. 2026 sales guidance increased to $680–$700 million. Volixibat and zilurgisertib advanced in regulatory and clinical milestones, while cash reserves strengthened.
Original document: Mirum Pharmaceuticals, Inc. [MIRM] SEC 8-K Current Report — Aug. 5 2026